Publications

1. Dagenais S, Mayer JM, Haldeman S, Borg-Stein J. Evidence informed management of chronic low back pain with intraligamentous injections of sclerosing solutions (prolotherapy). Spine J (in press).

2. Dagenais S, Mayer J, Wooley J, Haldeman S, Hite M. Acute toxicity evaluation of Proliferol: a dose- escalating, placebo-controlled study in rats. Int J Toxicol 2007;26(5):451-63.

3. Dagenais S, Yelland MJ, Del Mar C, Schoene ML. Prolotherapy injections for chronic low-back pain. Cochrane Database Syst Rev, 2007;2:CD004059.

4. Dagenais S, Prolotherapy for low back pain, January 2007,
http://www.spine-health.com/topics/conserv/prolotherapy/prolotherapy01.html

5. Dagenais S. Complementary medicine committee perspective, roundtable discussion: Prolotherapy, SpineLine, September/October 2006: 30-35.

6. Dagenais S, Ogunseitan O, Haldeman S, Wooley JR, Zaldivar F, Kim RC. Acute toxicity pilot evaluation of Proliferol in rats and swine. Int J Toxicol 2006;25(3):171-81.

7. Dagenais S, Ogunseitan O, Haldeman S, Wooley JR, Newcomb RL. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: a survey of practitioners. Arch Phys Med Rehabil. 2006;87(7):909-13.

8. Dagenais S, Haldeman S, Wooley JR. Intraligamentous injection of sclerosing solutions (“prolotherapy”) for spinal pain: a critical review of the literature. Spine J. 2005;5(3):310-28.

9. Dagenais S, Haldeman S, Wooley J. Authors' reply to Drs. Watson and Oppenheim. Spine J. 2006 Jan-Feb;6(1):103

10. Dagenais S, Multifactorial safety assessment of Proliferol, an investigational new drug for chronic low back pain: Adverse events, acute toxicity, and environmental loading. Published by UMI ProQuest for the University of California, Irvine, 2005, 269 pages, AAT 3160702.